Literature DB >> 16393298

Stability of irritable bowel syndrome using a Rome II-based classification.

R E Williams1, C L Black, H-Y Kim, E B Andrews, A W Mangel, J J Buda, S F Cook.   

Abstract

BACKGROUND: As there is no biological marker for irritable bowel syndrome, a diagnosis is made using symptom-based criteria. AIM: To evaluate the stability of self-reported symptoms consistent with Rome II-based irritable bowel syndrome classification.
METHODS: Irritable bowel syndrome subjects identified in a 2001 population-based study by modified Rome II criteria were re-contacted 2 years later. Data were collected via a web-based questionnaire.
RESULTS: Of the 697 subjects, 30% remained in the same irritable bowel syndrome subtype in both surveys, 18.4% changed irritable bowel syndrome subtype and 52% no longer met the irritable bowel syndrome criteria at follow-up. Subjects continuing to meet the irritable bowel syndrome criteria were more likely to have been initially classified in the alternating irritable bowel syndrome subtype and had more psychological impairment and lower irritable bowel syndrome-related quality of life than subjects not fulfilling the irritable bowel syndrome criteria at follow-up. Lack of pain caused more subjects to fall out of the irritable bowel syndrome criteria than the absence of non-painful bowel symptoms. However, the majority of subjects that did not fulfill the pain component of the irritable bowel syndrome criteria continued to report abdominal pain of at least moderate severity.
CONCLUSION: In a US population-based follow-up study using modified Rome II criteria, we found irritable bowel syndrome is episodic in nature and current classification is limited in capturing fluctuation of disease over time.

Entities:  

Mesh:

Year:  2006        PMID: 16393298     DOI: 10.1111/j.1365-2036.2006.02723.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

Review 1.  IBS--review and what's new.

Authors:  Amy Foxx-Orenstein
Journal:  MedGenMed       Date:  2006-07-26

2.  Subtypes of irritable bowel syndrome in children and adolescents.

Authors:  Mariella M Self; Danita I Czyzewski; Bruno P Chumpitazi; Erica M Weidler; Robert J Shulman
Journal:  Clin Gastroenterol Hepatol       Date:  2014-01-29       Impact factor: 11.382

3.  Irritable bowel syndrome: more than abdominal pain and bowel habit abnormalities.

Authors:  Brian Bond; Judith Quinlan; George E Dukes; Fermin Mearin; Ray E Clouse; David H Alpers
Journal:  Clin Gastroenterol Hepatol       Date:  2008-08-19       Impact factor: 11.382

4.  GP perspectives of irritable bowel syndrome--an accepted illness, but management deviates from guidelines: a qualitative study.

Authors:  Elaine F Harkness; Val Harrington; Sue Hinder; Sarah J O'Brien; David G Thompson; Paula Beech; Carolyn A Chew-Graham
Journal:  BMC Fam Pract       Date:  2013-06-27       Impact factor: 2.497

5.  Non-pharmacological treatments for irritable bowel syndrome: study protocol of an umbrella review of systematic review and meta-analyses.

Authors:  Song Jin; Yi-Fan Li; Di Qin; Dan-Qing Luo; Hong Guo; Xiu-Hua Gao; Ling Yue; Hui Zheng
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

6.  Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome.

Authors:  Zsa Zsa R M Weerts; Lisa Vork; Zlatan Mujagic; Daniel Keszthelyi; Martine A M Hesselink; Joanna Kruimel; Carsten Leue; Jean W M Muris; Daisy M A E Jonkers; Ad A M Masclee
Journal:  Neurogastroenterol Motil       Date:  2019-05-22       Impact factor: 3.598

7.  Using read codes to identify patients with irritable bowel syndrome in general practice: a database study.

Authors:  Elaine F Harkness; Laura Grant; Sarah J O'Brien; Carolyn A Chew-Graham; David G Thompson
Journal:  BMC Fam Pract       Date:  2013-12-02       Impact factor: 2.497

8.  Efficacy and safety of non-pharmacological interventions for irritable bowel syndrome in adults.

Authors:  Yun-Kai Dai; Yun-Bo Wu; Ru-Liu Li; Wei-Jing Chen; Chun-Zhi Tang; Li-Ming Lu; Ling Hu
Journal:  World J Gastroenterol       Date:  2020-11-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.